SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-342397
Filing Date
2021-11-29
Accepted
2021-11-29 17:09:54
Documents
12
Period of Report
2021-11-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d244160d8k.htm   iXBRL 8-K 27438
  Complete submission text file 0001193125-21-342397.txt   154959

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20211124.xsd EX-101.SCH 2889
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20211124_lab.xml EX-101.LAB 18888
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20211124_pre.xml EX-101.PRE 11858
5 EXTRACTED XBRL INSTANCE DOCUMENT d244160d8k_htm.xml XML 3479
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 211457206
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences